Drug-drug plasma protein binding interactions of ivacaftor

Journal of Molecular Recognition

Volumn 28, Issue 6, 2015, Pages 339-348

  Schneider, Elena K ^a,b   Huang, Johnny X ^c   Carbone, Vincenzo ^d   Baker, Mark ^e   Azad, Mohammad A K ^a   Cooper, Matthew A ^c   Li, Jian ^a   Velkov, Tony ^a  

^a MONASH UNIVERSITY   (Australia)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d AGRESEARCH GRASSLANDS   (New Zealand)

^e UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

binding affinity; cystic fibrosis; human serum albumin; human 1 acid glycoprotein; ivacaftor

Indexed keywords

AMINOPHENOL DERIVATIVE; ANTICOAGULANT AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; OROSOMUCOID; PROTEIN BINDING; QUINOLONE DERIVATIVE; SERUM ALBUMIN; WARFARIN;

AGONISTS; CHEMISTRY; DRUG INTERACTION; HUMAN;

AMINOPHENOLS; ANTICOAGULANTS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG INTERACTIONS; HUMANS; OROSOMUCOID; PROTEIN BINDING; QUINOLONES; SERUM ALBUMIN; WARFARIN;

EID: 84928106071     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.2447     Document Type: Article

References (62)

1. Azad MA, Huang JX, Cooper MA, Roberts KD, Thompson PE, Nation RL,. 2012. Structure-activity relationships for the binding of polymyxins with human alpha-1-acid glycoprotein. Biochem. Pharmacol. 84: 278-291.
2. Bear CE, Li C, Galley K, Wang Y, Garami E, Ramjeesingh M,. 1997. Coupling of ATP hydrolysis with channel gating by purified, reconstituted CFTR. J. Bioenerg. Biomembr. 29: 465-473.
3. Bhattacharya AA, Grune T, Curry S,. 2000. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol. 303: 721-732.
4. Bobadilla JL, Macek M, Jr., Fine JP, Farrell PM,. 2002. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum. Mutat. 19: 575-606.
5. Breustedt DA, Schonfeld DL, Skerra A,. 2006. Comparative ligand-binding analysis of ten human lipocalins. Biochim. Biophys. Acta 1764: 161-173.
6. Brown MB, Miller JN, Seare NJ,. 1995. An Investigation of the Use of Nile-Red as a Long-Wavelength Fluorescent-Probe for the Study of Alpha(1)-Acid Glycoprotein-Drug Interactions. J. Pharm. Biomed. Anal. 13: 1011-1017.
7. Carter DC, Ho JX,. 1994. Structure of serum albumin. Adv. Protein Chem. 45: 153-203.
8. Cheung JC, Kim Chiaw P, Pasyk S, Bear CE,. 2008. Molecular basis for the ATPase activity of CFTR. Arch. Biochem. Biophys. 476: 95-100.
9. Curry S, Mandelkow H, Brick P, Franks N,. 1998. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 5: 827-835.
10. Dean M, Santis G,. 1994. Heterogeneity in the severity of cystic fibrosis and the role of CFTR gene mutations. Hum. Genet. 93: 364-368.
11. Dudley MN, Blaser J, Gilbert D, Zinner SH,. 1990. Significance of extravascular protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection. Antimicrob. Agents Chemother. 34: 98-101.
12. Eap CB, Fischer JF, Baumann P,. 1991. Variations in relative concentrations of variants of human alpha 1-acid glycoprotein after acute-phase conditions. Clin. Chim. Acta 203: 379-385.
13. Eckford PD, Bear CE,. 2011. Targeting the regulation of CFTR channels. Biochem. J. 435: e1-e4.
14. Eckford PD, Li C, Ramjeesingh M, Bear CE,. 2012. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 287: 36639-36649.
15. Er JC, Vendrell M, Tang MK, Zhai D, Chang YT,. 2013. Fluorescent dye cocktail for multiplex drug-site mapping on human serum albumin. ACS Comb. Sci. 15: 452-457.
16. Essassi D, Zini R, Tillement JP,. 1990. Use of 1-anilino-8-naphthalene sulfonate as a fluorescent probe in the investigation of drug interactions with human alpha-1-acid glycoprotein and serum albumin. J. Pharm. Sci. 79: 9-13.
17. Flower DR,. 2000. Experimentally determined lipocalin structures. Biochim. Biophys. Acta 1482: 46-56.
18. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL,. 2012. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142: 718-724.
19. Fournier T, Medjoubi NN, Porquet D,. 2000. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta 1482: 157-171.
20. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S,. 2005. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 353: 38-52.
21. Greenblatt DJ, Sellers EM, Koch-Weser J,. 1982. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J. Clin. Pharmacol. 22: 259-263.
22. He XM, Carter DC,. 1992. Atomic structure and chemistry of human serum albumin. Nature 358: 209-215.
23. Hervé F, Caron G, Duché J-C, Gaillard P, Abd. Rahman N, Tsantili-Kakoulidou A,. 1998. Ligand specificity of the genetic variants of human α1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the a variant. Mol. Pharmacol. 54: 129-138.
24. Herve F, Gomas E, Duche JC, Tillement JP,. 1993. Fractionation of the genetic variants of human alpha 1-acid glycoprotein in the native form by chromatography on an immobilized copper(II) affinity adsorbent. Heterogeneity of the separate variants by isoelectrofocusing and by concanavalin A affinity chromatography. J. Chromatogr. 615: 47-57.
25. Hochepied T, Berger FG, Baumann H, Libert C,. 2003. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 14: 25-34.
26. Israili ZH, Dayton PG,. 2001. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 33: 161-235.
27. Jih KY, Hwang TC,. 2013. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc. Natl. Acad. Sci. U. S. A. 110: 4404-4409.
28. Johansen AK, Willassen NP, Sager G,. 1992. Fluorescence studies of beta-adrenergic ligand binding to alpha 1-acid glycoprotein with 1-anilino-8-naphthalene sulfonate, isoprenaline, adrenaline and propranolol. Biochem. Pharmacol. 43: 725-729.
29. Kidd JF, Ramjeesingh M, Stratford F, Huan LJ, Bear CE,. 2004. A heteromeric complex of the two nucleotide binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) mediates ATPase activity. J. Biol. Chem. 279: 41664-41669.
30. Kim Chiaw P, Eckford PD, Bear CE,. 2011. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. Essays Biochem. 50: 233-248.
31. Kogan I, Ramjeesingh M, Huan LJ, Wang Y, Bear CE,. 2001. Perturbation of the pore of the cystic fibrosis transmembrane conductance regulator (CFTR) inhibits its atpase activity. J. Biol. Chem. 276: 11575-11581.
32. Kogan I, Ramjeesingh M, Li C, Bear CE,. 2002. Studies of the molecular basis for cystic fibrosis using purified reconstituted CFTR protein. Methods Mol. Med. 70: 143-157.
33. Kremer JM, Wilting J, Janssen LH,. 1988. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40: 1-47.
34. Kristensen CB,. 1983. Imipramine serum protein binding in healthy subjects. Clin. Pharmacol. Ther. 34: 689-694.
35. Merrikin DJ, Briant J, Rolinson GN,. 1983. Effect of protein binding on antibiotic activity in vivo. J. Antimicrob. Chemother. 11: 233-238.
36. Myers LB,. 2009. The role of adherence, importance and burden from Cystic fibrosis etiology, diagnosis and treatments. Treatments for Cystic fibrosis, Leatte PN, (ed). Nova Biomedical: Hauppauge NY, USA.
37. Nishi K, Ono T, Nakamura T, Fukunaga N, Izumi M, Watanabe H,. 2011. Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1S forms. J. Biol. Chem. 286: 14427-14434.
38. Ojala PJ, Hermansson M, Tolvanen M, Polvinen K, Hirvonen T, Impola U,. 2006. Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry 45: 14021-14031.
39. Otagiri M,. 2005. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab. Pharmacokinet. 20: 309-323.
40. Ramjeesingh M, Ugwu F, Stratford FL, Huan LJ, Li C, Bear CE,. 2008. The intact CFTR protein mediates ATPase rather than adenylate kinase activity. Biochem. J. 412: 315-321.
41. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P,. 2011. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365: 1663-1672.
42. Reznikov LR, Abou Alaiwa MH, McElvaney NG, Tullis E, Bell SC, Drevinek P,. 2014. Antibacterial properties of the CFTR potentiator ivacaftor. J. Cyst. Fibros. 13: 515-519.
43. Ryan AJ, Ghuman J, Zunszain PA, Chung CW, Curry S,. 2013. Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin. J. Struct. Biol. 174: 84-91.
44. Schmidt S, Rock K, Sahre M, Burkhardt O, Brunner M, Lobmeyer MT,. 2008. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob. Agents Chemother. 52: 3994-4000.
45. Schonfeld DL, Ravelli RB, Mueller U, Skerra A,. 2008. The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J. Mol. Biol. 384: 393-405.
46. Skerra A,. 2000. Lipocalins as a scaffold. Biochim. Biophys. Acta 1482: 337-350.
47. Smith AE,. 1995. Treatment of cystic fibrosis based on understanding CFTR. J. Inherit. Metab. Dis. 18: 508-516.
48. Solomon M,. 2009. Cystic fibrosis-update on diagnosis and treatment from Cystic fibrosis etiology, diagnosisn and treatments. Treatments for Cystic fibrosis, Leatte PN, (ed). Nova Biomedical: Hauppauge NY, USA.
49. Sudlow G, Birkett DJ, Wade DN,. 1975. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 11: 824-832.
50. Sudlow G, Birkett DJ, Wade DN,. 1976. Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 12: 1052-1061.
51. Sugiyama Y, Suzuki Y, Sawada Y, Kawasaki S, Beppu T, Iga T,. 1985. Auramine O as a fluorescent probe for the binding of basic drugs to human alpha 1-acid glycoprotein (alpha 1-AG). The development of a simple fluorometric method for the determination of alpha 1-AG in human serum. Biochem. Pharmacol. 34: 821-829.
52. Tizzano EF, Buchwald M,. 1995. CFTR expression and organ damage in cystic fibrosis. Ann. Intern. Med. 123: 305-308.
53. Tsui LC,. 1992. Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Hum. Mutat. 1: 197-203.
54. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T,. 2009. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. U. S. A. 106: 18825-18830.
55. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD,. 2003. Improved protein-ligand docking using GOLD. Proteins 52: 609-623.
56. Voulgari F, Cummins P, Gardecki TI, Beeching NJ, Stone PC, Stuart J,. 1982. Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. Br. Heart J. 48: 352-356.
57. Welsh MJ, Smith AE,. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73: 1251-1254.
58. WHO. 2002. The molecular genetic epidemiology of cystic fibrosis.
59. Wine JJ, Brayden DJ, Hagiwara G, Krouse ME, Law TC, Muller UJ,. 1991. Cystic fibrosis, the CFTR, and rectifying Cl- channels. Adv. Exp. Med. Biol. 290: 253-269; discussion 269-272.
60. Wise R,. 1985. The relevance of pharmacokinetics to in-vitro models: protein binding - does it matter? J. Antimicrob. Chemother. 15: 77-83. Suppl A.
61. Wise R,. 1986. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin. Pharmacokinet. 11: 470-482.
62. Zsila F, Mady G,. 2008. Biliverdin is the endogenous ligand of human serum alpha(1)-acid glycoprotein. Biochem. Biophys. Res. Commun. 372: 503-507.